Lancet Infectious Diseases, The, ISSN 1473-3099, 2016, Volume 16, Issue 4, pp. e34 - e46
Summary Tuberculosis is the leading infectious cause of death worldwide, with 9·6 million cases and 1·5 million deaths reported in 2014. WHO estimates 480 000...
Infectious Disease | CULTURE CONVERSION | INFECTIOUS DISEASES | ORAL PHOSPHODIESTERASE-4 INHIBITOR | BLOOD BACTERICIDAL ACTIVITY | MEROPENEM-CLAVULANATE | NONREPLICATING MYCOBACTERIUM-TUBERCULOSIS | MULTIDRUG-RESISTANT TUBERCULOSIS | PULMONARY TUBERCULOSIS | DOUBLE-BLIND | STANDARDIZED TREATMENT | RANDOMIZED CONTROLLED-TRIAL | Anti-Infective Agents - pharmacology | Humans | Tuberculosis - drug therapy | Antitubercular Agents - pharmacology | Biomarkers - analysis | Anti-Infective Agents - therapeutic use | Drug Discovery | Mycobacterium tuberculosis - drug effects | Antitubercular Agents - therapeutic use | Tuberculosis, Multidrug-Resistant - drug therapy | Prevention | Tuberculosis | Lung diseases | Mortality | Development and progression | Anti-infective agents | Antitubercular agents | Respiratory agents | Drug resistance | Biological markers | Gene expression | Drug approval | Proteins | Studies | Hematology | Research & development--R&D | Protein synthesis | Biomarkers | Drug dosages
Infectious Disease | CULTURE CONVERSION | INFECTIOUS DISEASES | ORAL PHOSPHODIESTERASE-4 INHIBITOR | BLOOD BACTERICIDAL ACTIVITY | MEROPENEM-CLAVULANATE | NONREPLICATING MYCOBACTERIUM-TUBERCULOSIS | MULTIDRUG-RESISTANT TUBERCULOSIS | PULMONARY TUBERCULOSIS | DOUBLE-BLIND | STANDARDIZED TREATMENT | RANDOMIZED CONTROLLED-TRIAL | Anti-Infective Agents - pharmacology | Humans | Tuberculosis - drug therapy | Antitubercular Agents - pharmacology | Biomarkers - analysis | Anti-Infective Agents - therapeutic use | Drug Discovery | Mycobacterium tuberculosis - drug effects | Antitubercular Agents - therapeutic use | Tuberculosis, Multidrug-Resistant - drug therapy | Prevention | Tuberculosis | Lung diseases | Mortality | Development and progression | Anti-infective agents | Antitubercular agents | Respiratory agents | Drug resistance | Biological markers | Gene expression | Drug approval | Proteins | Studies | Hematology | Research & development--R&D | Protein synthesis | Biomarkers | Drug dosages
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2017, Volume 17, Issue 1, pp. 39 - 49
Summary Background Tuberculosis is the world's leading infectious disease killer. We aimed to identify shorter, safer drug regimens for the treatment of...
Infectious Disease | MYCOBACTERIUM-TUBERCULOSIS | DRUG | INFECTIOUS DISEASES | SOLID CULTURE | PHARMACOKINETICS | SPUTUM | PULMONARY TUBERCULOSIS | PHASE-II | RANGING TRIAL | COMBINATION | ANTITUBERCULOSIS TREATMENT | Drug Administration Schedule | Humans | Tanzania | Fluoroquinolones - therapeutic use | Male | Tuberculosis, Pulmonary - drug therapy | Ethylenediamines - therapeutic use | Pyrazinamide - therapeutic use | Tuberculosis, Pulmonary - diagnosis | Adamantane - therapeutic use | Adult | Female | Isoniazid - therapeutic use | Rifampin - therapeutic use | South Africa | Drug Therapy, Combination | Ethambutol - therapeutic use | Adamantane - analogs & derivatives | Antitubercular Agents - therapeutic use | Medical colleges | Tuberculosis | Pharmacy | Communicable diseases | Lung diseases | Clinical trials | Drugstores | Dosage and administration | Research institutes | Rifampin | Public health | Moxifloxacin | Analysis | Studies | Consortia | Drug dosages
Infectious Disease | MYCOBACTERIUM-TUBERCULOSIS | DRUG | INFECTIOUS DISEASES | SOLID CULTURE | PHARMACOKINETICS | SPUTUM | PULMONARY TUBERCULOSIS | PHASE-II | RANGING TRIAL | COMBINATION | ANTITUBERCULOSIS TREATMENT | Drug Administration Schedule | Humans | Tanzania | Fluoroquinolones - therapeutic use | Male | Tuberculosis, Pulmonary - drug therapy | Ethylenediamines - therapeutic use | Pyrazinamide - therapeutic use | Tuberculosis, Pulmonary - diagnosis | Adamantane - therapeutic use | Adult | Female | Isoniazid - therapeutic use | Rifampin - therapeutic use | South Africa | Drug Therapy, Combination | Ethambutol - therapeutic use | Adamantane - analogs & derivatives | Antitubercular Agents - therapeutic use | Medical colleges | Tuberculosis | Pharmacy | Communicable diseases | Lung diseases | Clinical trials | Drugstores | Dosage and administration | Research institutes | Rifampin | Public health | Moxifloxacin | Analysis | Studies | Consortia | Drug dosages
Journal Article
Lancet, The, ISSN 0140-6736, 2010, Volume 375, Issue 9732, pp. 2179 - 2191
Summary The Millennium Development Goal target for tuberculosis control is to halt the spread of tuberculosis by 2015, and begin to reverse the worldwide...
Internal Medicine | Financial Support | AIDS-Related Opportunistic Infections - prevention & control | Health Services | Global Health | Humans | Tuberculosis - drug therapy | Tuberculosis - prevention & control | AIDS-Related Opportunistic Infections - drug therapy | AIDS-Related Opportunistic Infections - diagnosis | Research | Health Priorities | Tuberculosis - diagnosis | Care and treatment | Control | Tuberculosis | Diagnosis
Internal Medicine | Financial Support | AIDS-Related Opportunistic Infections - prevention & control | Health Services | Global Health | Humans | Tuberculosis - drug therapy | Tuberculosis - prevention & control | AIDS-Related Opportunistic Infections - drug therapy | AIDS-Related Opportunistic Infections - diagnosis | Research | Health Priorities | Tuberculosis - diagnosis | Care and treatment | Control | Tuberculosis | Diagnosis
Journal Article
Lancet Global Health, ISSN 2214-109X, 2016, Volume 4, Issue 11, pp. e806 - e815
Summary Background The post-2015 End TB Strategy proposes targets of 50% reduction in tuberculosis incidence and 75% reduction in mortality from tuberculosis...
Internal Medicine | TRANSMISSION | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | HIV | DISEASE | BURDEN | DIAGNOSTICS | BENEFITS | Models, Theoretical | Tuberculosis - epidemiology | World Health Organization | Humans | Forecasting | Cause of Death | Incidence | India | Mass Screening | Tuberculosis - therapy | Delivery of Health Care | Health Services Accessibility | China | Tuberculosis - prevention & control | HIV Infections - complications | Isoniazid - therapeutic use | South Africa | Achievement | Goals | Tuberculosis - transmission | Antitubercular Agents - therapeutic use
Internal Medicine | TRANSMISSION | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | HIV | DISEASE | BURDEN | DIAGNOSTICS | BENEFITS | Models, Theoretical | Tuberculosis - epidemiology | World Health Organization | Humans | Forecasting | Cause of Death | Incidence | India | Mass Screening | Tuberculosis - therapy | Delivery of Health Care | Health Services Accessibility | China | Tuberculosis - prevention & control | HIV Infections - complications | Isoniazid - therapeutic use | South Africa | Achievement | Goals | Tuberculosis - transmission | Antitubercular Agents - therapeutic use
Journal Article
Lancet Global Health, ISSN 2214-109X, 2017, Volume 5, Issue 7, pp. e710 - e719
Summary Background In 2010 a new diagnostic test for tuberculosis, Xpert MTB/RIF, received a conditional programmatic recommendation from WHO. Several...
Internal Medicine | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | SERVICES | INCOME | EMPIRICAL-TREATMENT | OUTCOMES | MICROSCOPY | BURDEN | DRUG-RESISTANT TUBERCULOSIS | Quality-Adjusted Life Years | Sputum - microbiology | Tuberculosis - epidemiology | Cost-Benefit Analysis | Humans | South Africa - epidemiology | Female | Male | Drug Resistance, Bacterial - drug effects | Tuberculosis - diagnosis
Internal Medicine | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | SERVICES | INCOME | EMPIRICAL-TREATMENT | OUTCOMES | MICROSCOPY | BURDEN | DRUG-RESISTANT TUBERCULOSIS | Quality-Adjusted Life Years | Sputum - microbiology | Tuberculosis - epidemiology | Cost-Benefit Analysis | Humans | South Africa - epidemiology | Female | Male | Drug Resistance, Bacterial - drug effects | Tuberculosis - diagnosis
Journal Article
Lancet Global Health, ISSN 2214-109X, 2016, Volume 4, Issue 11, pp. e816 - e826
Summary Background The post-2015 End TB Strategy sets global targets of reducing tuberculosis incidence by 50% and mortality by 75% by 2025. We aimed to assess...
Internal Medicine | DIAGNOSIS | TARGETS | DECISIONS | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | BURDEN | DISEASE | Models, Theoretical | Quality-Adjusted Life Years | Tuberculosis - mortality | Humans | Health Expenditures | Tuberculosis - economics | Forecasting | India | Health Services Needs and Demand | Health Care Costs | Delivery of Health Care - economics | Patient Acceptance of Health Care | Health Services Accessibility | China | Cost-Benefit Analysis | Tuberculosis - prevention & control | South Africa | Goals | Health Policy | Health Resources
Internal Medicine | DIAGNOSIS | TARGETS | DECISIONS | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | BURDEN | DISEASE | Models, Theoretical | Quality-Adjusted Life Years | Tuberculosis - mortality | Humans | Health Expenditures | Tuberculosis - economics | Forecasting | India | Health Services Needs and Demand | Health Care Costs | Delivery of Health Care - economics | Patient Acceptance of Health Care | Health Services Accessibility | China | Cost-Benefit Analysis | Tuberculosis - prevention & control | South Africa | Goals | Health Policy | Health Resources
Journal Article
Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9748, pp. 1244 - 1253
Summary Background Control of tuberculosis in settings with high HIV prevalence is a pressing public health priority. We tested two active case-finding...
Internal Medicine | MEDICINE, GENERAL & INTERNAL | TRANSMISSION | SUB-SAHARAN AFRICA | ERA | MALAWI | ANTIRETROVIRAL THERAPY | PATIENT | HIGH HIV PREVALENCE | BURDEN | KAMPALA | UGANDA | Sputum - microbiology | Zimbabwe - epidemiology | Prevalence | Community Health Workers | HIV Seropositivity - complications | Humans | Middle Aged | Male | Tuberculosis, Pulmonary - prevention & control | Community Health Services - methods | Tuberculosis, Pulmonary - diagnosis | Mobile Health Units | HIV Seropositivity - epidemiology | Adult | Female | Tuberculosis, Pulmonary - epidemiology | Microscopy, Fluorescence | Cluster Analysis | Control | Disease transmission | Tuberculosis | Diagnosis | Risk factors | Methods | Infection control | Studies | Intervention | Biomedical research | Households | Public health | Monitoring systems | Fast track
Internal Medicine | MEDICINE, GENERAL & INTERNAL | TRANSMISSION | SUB-SAHARAN AFRICA | ERA | MALAWI | ANTIRETROVIRAL THERAPY | PATIENT | HIGH HIV PREVALENCE | BURDEN | KAMPALA | UGANDA | Sputum - microbiology | Zimbabwe - epidemiology | Prevalence | Community Health Workers | HIV Seropositivity - complications | Humans | Middle Aged | Male | Tuberculosis, Pulmonary - prevention & control | Community Health Services - methods | Tuberculosis, Pulmonary - diagnosis | Mobile Health Units | HIV Seropositivity - epidemiology | Adult | Female | Tuberculosis, Pulmonary - epidemiology | Microscopy, Fluorescence | Cluster Analysis | Control | Disease transmission | Tuberculosis | Diagnosis | Risk factors | Methods | Infection control | Studies | Intervention | Biomedical research | Households | Public health | Monitoring systems | Fast track
Journal Article
Lancet Respiratory Medicine, The, ISSN 2213-2600, 2017, Volume 5, Issue 4, pp. 291 - 360
Summary Global tuberculosis incidence has declined marginally over the past decade, and tuberculosis remains out of control in several parts of the world...
Pulmonary/Respiratory | MYCOBACTERIUM-TUBERCULOSIS | HOLLOW-FIBER MODEL | RESPIRATORY SYSTEM | NEW-YORK-CITY | POPULATION PHARMACOKINETICS | COMMUNITY-BASED TREATMENT | PULMONARY TUBERCULOSIS | DIRECTLY OBSERVED THERAPY | SPUTUM CULTURE CONVERSION | HIV-INFECTED PATIENTS | MDR-TB PATIENTS | CRITICAL CARE MEDICINE | Prevention | Chemotherapy | Usage | Tuberculosis | Disease transmission | Diagnosis | Cancer
Pulmonary/Respiratory | MYCOBACTERIUM-TUBERCULOSIS | HOLLOW-FIBER MODEL | RESPIRATORY SYSTEM | NEW-YORK-CITY | POPULATION PHARMACOKINETICS | COMMUNITY-BASED TREATMENT | PULMONARY TUBERCULOSIS | DIRECTLY OBSERVED THERAPY | SPUTUM CULTURE CONVERSION | HIV-INFECTED PATIENTS | MDR-TB PATIENTS | CRITICAL CARE MEDICINE | Prevention | Chemotherapy | Usage | Tuberculosis | Disease transmission | Diagnosis | Cancer
Journal Article